BioSpace News Archive

Covalon Technologies Ltd., an advanced medical technologies company, will release its Q4 and year end Fiscal 2021 financial results on Monday, December 13, 2021 before markets open.

Samsung Bioepis Co., Ltd. today announced that SB3 (ONTRUZANT®, trastuzumab-dttb), a biosimilar to Herceptin® (trastuzumab), demonstrated comparable long-term survival results between SB3 and reference trastuzumab (TRZ) after a median follow-up of 68 months from the randomization of the SB3 Phase 3 study.

Prestige BioPharma Ltd. (KRX: 950210) and Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, hereafter referred to as “Dr. Reddy’s”) today announced that the two companies have entered into a binding agreement for an exclusive partnership for the supply and commercialization of Prestige BioPharma’s proposed trastuzumab biosimilar in select countries in Latin America and Southeast Asia.

AstraZeneca’s EVUSHELD (tixagevimab co-packaged with cilgavimab), a long-acting antibody (LAAB) combination, has received emergency use authorization (EUA) in the US for the pre-exposure prophylaxis (prevention) of COVID-19, with first doses expected to become available very soon.

Relmada Therapeutics, Inc., a late-stage biotechnology company addressing diseases of the central nervous system, announced the pricing of an upsized underwritten public offering of 8,823,530 shares of its common stock at a public offering price of $17.00 per share.

Nomic Bio (“Nomic”), the protein profiling company, today announced the closing of an oversubscribed US$17 million Series A funding round, bringing the company’s total funding to date to over US$21 million.

Alpha-1 Biologics Announces Positive Data Published in frontiers in Oncology on Alphataxin in Combination with Anti-PD-1 Therapy that Suppressed Murine Renal Cancer and Metastasis.

Takeda Pharmaceutical Company today announced that the data from the pivotal Phase 3 SOLSTICE clinical trial of LIVTENCITY were published in the journal of Clinical Infectious Diseases (CID).

BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will hold a digital press conference on Wednesday, December 8, 2021, to present the results from initial laboratory studies which started about two weeks ago.

Amphera B.V. announces significant progress in its two clinical programs in pancreatic cancer as well as the full recruitment of all patients in its pivotal Phase II/III study in mesothelioma.